Healing of Long-term Frozen Orthotopic Bone Allografts is not Affected by MHC Differences Between Donor and Recipient by Reikerås, Olav et al.
BASIC RESEARCH
Healing of Long-term Frozen Orthotopic Bone Allografts is not
Affected by MHC Differences Between Donor and Recipient
Olav Reikera ˚s MD, PhD, Finn P. Reinholt MD, PhD,
Severin Zino ¨cker MSc, Hamid Shegarﬁ MSc,
Bent Rolstad MD, PhD
Received: 6 April 2010/Accepted: 13 December 2010/Published online: 3 February 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract
Background The use of bone grafting in orthopaedic sur-
gery has increased dramatically in recent years. However,
the degree to which immune responses are important for the
survival of the allograft is not fully understood. In particular
it remains unclear whether differences in the major histo-
compatibility complex (MHC) inﬂuence incorporation of
bone allografts and their subsequent biologic performance.
Questions/purposes Therefore, we asked whether isolated
mismatch for MHC antigens of deep frozen bone allografts
in the long-term causes (1) immune reactions, and whether
these reactions have any effect on (2) morphologic features
of the graft, (3) radiographic graft healing, and (4) graft
strength.
Methods We used an established orthotopic tibial seg-
ment transplantation technique that allows determination
of mechanical strength, histologic evaluation, and immune
responses. Tibial segments that had been deep-frozen at
80C for 1 year were transplanted into 24 PVG (RT1
c)
rats from either 12 syngeneic donors or 12 MHC congenic
donors PVG.1U (RT1
u). We determined immune respon-
ses using an indirect Coombs reaction and determined
graft healing radiographically and mechanically after
6 months.
Results We detected no alloantibody production to graft
MHC-I antigens, and found no differences between syn-
geneic and MHC mismatched grafts in terms of remodeling
with host bone, graft healing, and mechanical strength.
Conclusions Mismatches for MHC antigens do not seem
to play a decisive role in healing of long-term, deep-frozen
bone allografts.
Introduction
Bone is the second most transplanted tissue after blood and
is used to provide support, ﬁll voids, and enhance biologic
repair of skeletal defects. Autologous bone provides the
optimal source, but the harvest has considerable limita-
tions, including donor-site morbidity, inappropriate form,
and lack of sufﬁcient quantities in procedures requiring
large amounts of graft [1, 12]. This is of special concern in
revision surgery of failed total hip and knee prostheses, and
in limb salvaging resection of musculoskeletal tumors;
cadaver allograft is the only alternative.
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DOI 10.1007/s11999-011-1796-zGenerally, bone allografting is performed without tissue
matching between donors and recipients, but in processing
procedures, blood, bone marrow, and soft tissue are
removed and freezing and thawing of the donor bone
reduces the antigenicity. Antibodies against human leuko-
cyte antigen (HLA) are induced by mismatched bone
transplants [10, 30, 32], but it remains unknown whether
donor-speciﬁc HLA sensitization inﬂuences the incorpo-
ration of bone allografts and their subsequent biologic
performance. For example, Strong et al. [30] reported an
increase in HLA antibody sensitization from 39% to 67%
associated with bone allografts, but they were unsure if
there was any associated effect on allograft incorporation.
In general, the rate of failure with allograft reconstruc-
tion owing to complications has been reported to range
between 15% and 25% [3, 4, 6, 7, 9, 14, 15, 22]. However,
results vary to some extent with the type of graft, anatomic
site, and stage of the lesion, ie, the complexity of the surgery
and the relative necessity for chemotherapy. The most
important factors inﬂuencing graft survival are recurrence,
infection, nonunion, and fracture. Mankin et al. [14]
reported long-term results of allograft replacement in the
management of bone tumors and found an infection rate of
11%, nonunion rate of 17% and fracture rate of 19%. The
failure rate was highest in the ﬁrst year and declinedrapidly.
Mankin and Hornicek reviewed 144 patients with giant cell
tumors who had resection and implantation of cadaveric
allografts from 1971 to 2001 [15]. Most procedures were
done in the distal femur, proximal tibia, proximal femur,
and proximal humerus. Seventy-eight percent of patients
retained their grafts. Tumor complications included local
recurrences in eight patients and metastases in three. None
of the patients died. Allograft fracture occurred in 30 (21%)
of the 144 patients, nonunion occurred in 12 (8%), and
infection occurred in 12 (8%). Deijkers et al. [3] reported
three infections, 12 fractures, and nine nonunion treatments
in a 10-year followup of 35 grafts. Ultimately, six grafts
failed, with infection and length of resection as predispos-
ing factors. Muscolo et al. [17] reviewed 59 consecutive
patients after segmental resection in 52 for malignant bone
tumors and in seven for benign aggressive bone tumors.
They reported an overall 5-year survivorship of the patients
of 79%. Infection, nonunion, and fracture rates were 5%,
9%, and 7%, respectively.
Processed frozen bone allografts lack viable donor cells
and may trigger an indirect pathway of alloantigen recog-
nition in the recipient. The indirect pathway involves
presentation of processed allogeneic HLA shed from for-
eign cells through cell necrosis and apoptosis. Recipient
antigen presenting cells (APC) present the processed pep-
tides in the context of self-HLA Class II to MHC Class II
restricted CD4 + T cells [19, 25]. Degraded fragments in
frozen bone allografts represent potential immunogenic
proteins. This type of recognition may induce either a
chronic type of rejection or an immunologic state of tol-
erance to grafted antigens that cannot be measured with
human leukocyte blood tests. A chronic type of host-anti-
graft response may result in late deterioration of graft
function characterized by inﬂammation and interstitial
ﬁbrosis [5].
Clinical studies have some disadvantages when studying
HLA sensitization to bone allografts, such as blood trans-
fusions during surgery and the variability of the grafts in
terms of processing, implantation, ﬁxation techniques,
ﬁxation quality, complications, soft tissue envelope, peri-
osteal preservation, supplemental bone grafting at the
junctions, anatomic distribution, and use of radiation or
chemotherapy. Also, tissue injury in major surgery leads to
the release of endogenous damage-associated molecular
patterns that activate the innate immune cells, and one
study suggests antibodies to degraded bone soluble proteins
may develop in patients with osteoarthritis [31].
Therefore, we asked whether isolated mismatch for
MHC antigens of deep frozen bone allografts in the long-
term causes (1) immune reactions, and whether these
reactions have any effect on (2) morphologic features of
the graft, (3) radiographic graft healing, and (4) graft
strength.
Materials and Methods
For the experiment we obtained 24 PVG rats that
were operated on under general anesthesia (Hypnorm
1/
Dormicum
1, VetaPharma, Sheburn, Leeds, England)
(Fig. 1). Using an anterior incision, we exposed the prox-
imal part of either the right or left tibia and carefully
elevated the muscles. We then made two osteotomies at the
shaft of the bone, 8 mm and 16 mm from the knee, using a
ﬁne-toothed circular saw blade mounted on an electric
drill, and removed the segment. By random selection, the
rats received a transplant of either a deep frozen syngeneic
segment (PVG bone) or with a deep frozen allogeneic
segment (PVG.1U bone), from the bone bank. We inserted
a 0.8-mm steel pin (cannula), press ﬁt, for intramedullary
stabilization. The intact ﬁbula secured rotational stability.
We achieved ﬁxation without radiographic control, but
conﬁrmed proper pin placement using radiographs taken at
the end of the experiment. We performed the experiments
using aseptic technique.
The strength of deep frozen autogenous grafts in this
model attained approximately 70% of intact bone at
16 weeks [23]. We therefore assumed that with a followup
of 6 months the grafts would have attained the strength of
the intact bone. With a difference between the two exper-
imental groups of 15% as clinically interesting, six rats in
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123each group for biomechanical testing would have a power
of 80% with a two-tailed alpha of 0.05.
One year before the experiments, six PVG.1U (RT1
u)
and six PVG (RT1
c) rats (Harlan UK Limited, Shaw’s
Farm, Blackthorn, Bicester, England) were sacriﬁced and
both tibial bones were excised for the grafts. To make the
grafts we made two osteotomies at the shaft of the bones,
8 mm and 16 mm from the tibial plateau, using a ﬁne-
toothed circular saw blade mounted on an electric drill. By
careful steel burring to the endosteal cortex, we emptied
the bone segments of cancellous bone and bone marrow.
We then sealed and froze the 24 bone segments at 80C
in our bone bank system.
The PVG.1U and PVG rats are identical except for the
major histocompatibility complex (MHC of u haplotype
versus MHC of c haplotype), where PVG.1U rats have their
MHC (RT1) complex derived from the AO strain. There-
fore, an isolated effect of MHC mismatches (Class I, Class
II, and other polymorphic antigens in the MHC) on graft
survival and other biologic parameters can be monitored.
The experiment conformed to the Norwegian Council of
Animal Research Code for the Care and Use for Experi-
mental Purposes.
Postoperatively, one rat in each group died. We subcu-
taneously injected buprenorphine (Temgesic
1; Reckitt &
Benckiser, Slough, UK), 0.05 mg per kilo, twice daily for
the ﬁrst 3 postoperative days for analgesia, and observed
the rats daily for limb function and signs of improper
healing. They all resumed full weightbearing after a few
days. At 6 months, we sacriﬁced the animals with Pento-
barbital
1 (A ˚s produksjonslaboratorium, A ˚s, Norway),
100 mg/kg (0.1 mL/100 g) intraperitoneally (ie, 0.35 mL).
Postoperatively at the time of grafting and at termination
of the experiments after 6 months, we obtained blood via a
cannula from the tail vein of ﬁve rats from each group, and
blood serum was examined for antibodies against MHC
antigens. As described previously [20], we measured the
antibody response in individual rats. In short, we incubated
rat lymphoid cells, YB2/0, and expressing MHC-I (RT1
Class I) antigens of RTI
uu haplotype with serum dilutions
from the transplanted rats at 48C for 30 minutes, washed,
then incubated with a FITC-labeled secondary goat anti-rat
IgG heavy + light chain (Jackson ImmunoResearch Lab-
oratories, West Grove, PA, USA) for another 30 minutes
before washing again. We measured the ﬂuorescence
intensity in a FACScalibur (Becton Dickinson, San Jose,
CA, USA), with gates set to exclude dead cells. In this test
system, substantial antibody synthesis can be detected only
when the peak ﬂuorescence intensity has shifted so much to
the right that there is only partly or no overlap between the
two sets of curves. To show how an antibody response
manifests itself in this system, we also included a standard
mAb (NR5/10) against MHC Class I of the RT1u haplotype
(positive control). We conﬁrmed the validity of this method
in a clear shift of the histogram to the right as evaluated by
two of us (HS and BR).
The transplanted bones of these ﬁve animals of each
group then were harvested and ﬁxed by immersion in
4% phosphate-buffered formaldehyde immediately after
sacriﬁce, decalciﬁed for 3 weeks in 7% ethylenediamine-
tetraacetic acid (EDTA), and embedded in parafﬁn
according to a routine protocol. Sections were coded to
blind the observer regarding the experimental group from
which the section emanated. We used three to ﬁve hema-
toxylin and eosin-stained sections, including the central
marrow area, to evaluate the tissue. One of us (FPR) used
semiquantitative scoring with a three-grade scale (0, +,
++) to grade cortical integrity, identiﬁable remnants of
graft, marrow ﬁbrosis, and inﬂammation. The parameters
were scored as follows: (1) cortical integrity =+one
cortex intact, ++ both cortices intact; (2) identiﬁable
remnants of graft =+remnants observed in less than 50%
of the graft area, ++ remnants observed in greater than
50% of graft area; (3) marrow ﬁbrosis =+ﬁbrous tissue/
collagen ﬁbers in greater than 5% of the marrow area,
++ ﬁbrous tissue/collagen ﬁbers in greater than 20% of
the marrow area; (4) inﬂammation =+one focus with
more than 20 leukocytes in a high power ﬁeld of vision,
++ two or more such foci (Fig. 2). The grading was per-
formed twice by the same pathologist (FPR) at in interval
greater than 1 month, and the reproducibility of the semi-
quantitative scoring was 90% (kappa 0.825).
We subjected the remaining six rats in each group to
radiographic and biomechanical examinations. We har-
vestedtheirtransplantedandtheir intactlegs,andperformed
radiography of the transplanted leg with a standard clinical
digital system (Siemens Axiom Aristos; Siemens AG,
Bone Bank
12 PVG tibial bone transplants
12 PVG 1.U tibial bone transplants
12 months
Experiments
12 PVG rats transplanted with PVG transplants (MHC matched) pp ( )
12 PVG rats transplanted with PVG1.U transplants (MHC mismatched)
(One rat in  each group died postoperatively)
6 months
Radiology /
Mechanics
Immunology /
Histology
6 MHC matched rats
6 MHC mismatched rats
5 MHC matched rats
5 MHC mismatched rats
Fig. 1 A diagram of the experimental design is shown.
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lary pin. The xray tube settings were 46 kV, 1.0 mA per
second, and focus-to-ﬁlm-distance (source-to-image receptor
distance) of 115 cm. Two of us (OR, HS) assessed all
radiographs for healing using the following criteria:
(1)completehealing,deﬁnedasbonebridgingwithoutgaps,
(2) incomplete healing, deﬁned as a radiolucent gap with
some areas of bridging bone trabeculae, and (3) no healing,
deﬁned asacontinuousradiolucentgapattheosteotomysite
with no bridging bone trabeculae. Interobserver agreement
for radiographic healing was 100%.
After radiographic examinations, we examined the bone
mineral content (BMC) and density (BMD) of the trans-
planted and contralateral intact bones using dual energy
radiographic absorptiometry (DEXA). DEXA was per-
formed on a GE Lunar Piximus (Lunar Corporation,
Madison, WI, USA) with a tube current of 400 lA. The
frequency of the scanning unit was 50/60 Hz, and the xray
tube had a focal spot size of 0.25 mm by 0.25 mm with a
coefﬁcient variation of 1%. After scanning the whole tibia,
we centralized a region of interest at the graft.
Thereafter, we tested the composite (transplanted) and
the contralateral bones for torsional strength (MTS 858;
MTS Systems Corporation, Eden Prairie, MN, USA). We
ﬁxed the tibial ends with a clamp and ran the instrument at
a constant rate of 0.08 radii per second. The load values
were recorded and transformed to a load deformation curve
(Origin 7.5; OriginLab Corporation, Northampton, MA,
USA). We deﬁned the strength as the torsion necessary to
produce fracture of the composite bone. We determined the
torsion stiffness from the slope of the linear elastic part of
the curve and deﬁned the energy as the energy absorbed
during loading to fracture.
Data for biomechanical parameters and BMC and BMD
are presented as mean and standard deviation of the mean.
Data were normally distributed and were analyzed using
one-way ANOVA. Statistical analysis was performed with
SPSS 16.0 (SPSS Inc, Chicago, USA.)
Results
None of the ﬁve allotransplanted rats exhibited any
detectable antibody response as the FACS distribution
curves were identical to the controls (Fig. 3).
Fig. 2A–C (A) A low-power photomicrograph is shown that
includes the area of the graft, a bone with allogeneic graft on the
left, and a syngeneic graft on the right. Both bones show ++ bone
continuity (Stain, hematoxylin & eosin). Scale bar = 1.5 mm. (B)A
medium-power photomicrograph shows an area with remnant of the
graft outlined with arrows. The micrograph is from a bone with
++ remnants of implant (Stain, hematoxylin & eosin). Scale
bar = 200 lm. (C) Another medium-power photomicrograph shows
an area of bone marrow with dead bone (rounded structure in the
lower middle of the photomicrograph) surrounded by inﬂammatory
inﬁltrate and ﬁbrosis. This is from a + inﬂammation bone (Stain,
hematoxylin & eosin). Scale bar = 200 lm.
b
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cortical bone in the transplanted segment and adjacent
bone, except for one focal defect in one of the animals in
the allogeneic group (Fig. 2A; Table 1). We observed
remnants of the graft in greater than 50% of the trans-
planted segment in four of ﬁve bones in each group
(Fig. 2B). One animal in each group showed focal
inﬂammation surrounding remnants of devitalized bone
along with focal ﬁbrosis (Fig. 2C).
Complete radiographic healing of the grafted segment
occurred in all transplanted bones (Fig. 4).
Fig. 3A–C The FACS plots show no detectable antibody production
in PVG rats transplanted with either frozen bone from PVG
(syngeneic) or PVG.1U (allogeneic MHC mismatched) rats. The
ﬁnal serum dilution was 1/8. Propidium iodide was used for gating on
live cells. The plots show (A) FITC labeled secondary Ab alone (gray
ﬁlled), mAb OX6 against MHC-II (thin line) and a standard antibody
against MHC-I of the RT1u haplotype mAb NR5/10 (thick line),
(B) counts for three pretransplanted rats, and (C) from two
representative rats of each group (syngeneic [gray ﬁlled and stapled
line] and allogeneic [thin and thick lines]).
Table 1. Semiquantitative assessment of histologic features in 10
bones
Animal type/
number
Intact
cortex*
Rest of
implant

Marrow
ﬁbrosis

Inﬂammation
§
Allogeneic 1 ++ ++ 00
Allogeneic 2 ++ ++ 00
Allogeneic 3 ++ + 00
Allogeneic 4 ++ ++ 00
Allogeneic 5 ++ + + +
Syngeneic 1 ++ ++ 00
Syngeneic 2 ++ ++ 00
Syngeneic 3 ++ ++ 00
Syngeneic 4 ++ ++ 00
Syngeneic 5 ++ + + +
* Intact cortex =+one cortex intact, ++ both cortices intact;
rest
of implant =+remnants observed in less than 50% of the implant
area, ++ remnants observed in greater than 50% of implant area;
marrow ﬁbrosis =+ﬁbrous tissue/collagen ﬁbers in greater than
5% of the marrow area, ++ ﬁbrous tissue/collagen ﬁbers in greater
than 20% of the marrow area;
§inﬂammation =+one focus with
greater than 20 leukocytes in a high power ﬁeld of vision, ++ two or
more such foci.
Fig. 4A–B The radiographs show fully incorporated (A) frozen
allogeneic and (B) syngeneic grafts (between arrows) after 6 months.
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between the two groups (Table 2), and bone mineralization
was similar to that in the intact bones (Table 2). There
were no differences in torsion strength between the groups,
nor were there any differences in either stiffness or fracture
energy (Table 3). Furthermore, the biomechanical param-
eters of the transplanted bones were similar to those of the
intact bones (Table 3).
Discussion
Bone allografting is being used increasingly in patients for
bone reconstruction. However, on implantation of alloge-
neic bone, the host is expected to experience an intricate
immune response [5]. Deep freezing may reduce the
immunity, but also may alter the properties of the graft.
How these processes affect the incorporation of massive
bone allografts are not fully understood. Therefore, we
asked whether isolated mismatch for MHC antigens of
deep frozen bone allografts in the long-term causes
(1) immune reactions, and whether these reactions have
any effect on (2) morphologic features of the graft,
(3) radiographic graft healing, and (4) graft strength.
Our study is associated with certain limitations. First,
the results of experimental studies generally must be
transferred to human clinical practice with caution, espe-
cially in this case, based on the magnitude of the difference
in graft size and the inherent differences in the immune
systems. However, the rats in this study were genetically
identical except for the MHC region, and rats, in general,
are biologically similar to humans when it comes to the
biology of bone healing [21]. Second, we used intercalary
allografts, and our ﬁndings may be restricted to these kinds
of allografts. Third, the reproducibility of semiquantitative
histologic scoring systems is reportedly low [11], but we
believe semiquantitative scoring may be reasonable with a
high degree of reproducibility if the parameters are kept
basic and the grades are limited and well deﬁned [13].
Fourth, we had no direct data to establish power analyses
for continuous biomechanical data. However, our data
were normally distributed with a power for the null
hypothesis of 83% with a two-tailed alpha of 0.05. Fifth, a
torsion test is not osteotomy site-speciﬁc, as it determines
the weakest point of the bone rather than measuring the
strength at the osteotomy sites. If the graft healed, it may
be stronger than the entire bone. However, this is also why
torsion tests usually are applied to bone segments and
grafts.
In rats, the RT1 gene region on chromosome 20 encodes
MHC Classes I and II molecules that are highly polymor-
phic and provoke strong alloimmune responses to organ
transplantation, leading to their rejection. Based on dif-
ferences solely in the MHC region, PVG rats reject organ
grafts from PVG 1U rats. Strong antibody responses to
allogeneic MHC-I molecules after MHC mismatched
transplantation of fresh bone in this rat model have been
observed [24]. Direct recognition occurs when recipient Th
lymphocytes recognize MHC-II antigens on intact APC in
the allograft. Animal and human studies show that the
cellular components of bone express sufﬁcient MHC
molecules to alert the host immune system with activation
of cytotoxic T cells, leading to destruction of cells in the
graft [8, 18, 26]. Indirect recognition occurs when recipient
APC ingests donor MHC antigens from broken down cells
and present peptides of donor MHC in the groove of the
recipient’s own MHC molecules. This latter scenario may
be predominant when donor tissue is damaged by freezing,
and releases peptides that can lead to a more chronic state
of inﬂammation in the graft. To obtain a sufﬁcient IgG
response against MHC-I or II molecules, this will require
help from sensitized T cells. In the current study, none of
the ﬁve allotransplanted rats exhibited any detectable
antibody response; the FACS-distribution curves at
6 months were identical to the controls. This implies that
MHC-derived antigens from the donor were not present in
quantities that provoked a measurable antibody response.
However, we cannot formally exclude that low concen-
trations of donor antigens were taken up by host
macrophages or antigen presenting cells, and could pro-
voke an indirect antigen presentation to host T cells. Some
experimental studies reported an antibody response after
cryopreserved bone grafts [2, 19, 27, 29], but such reac-
tions usually are weak. Bos et al. [2] performed iliac crest
Table 2. BMC and BMD of the transplanted and intact bones
Mineralization Syngeneic Allogeneic Intact p Value
BMC (10
3 g) 41.8 ± 2.1* 44.6 ± 12.2 35.6 ± 3.4 0.364
BMD (10
3 g/cm
2) 19.9 ± 2.2 19.5 ± 4.2 17.4 ± 0.7 0.473
BMC = bone mineral content; BMD = bone mineral density;
* mean ± standard deviation.
Table 3. Biomechanics of the transplanted and intact bones
Biomechanics Syngeneic Allogenic Intact p Value
Moment
(Nm 9 10
2)
13.6 ± 2.60* 12.0 ± 2.54 14.0 ± 1.78 0.295
Stiffness
(Nm/degree
9 10
3)
3.06 ± 0.64 2.55 ± 0.60 3.06 ± 0.50 0.229
Energy
(Nm 9 degree
9 10
1)
66.7 ± 25.8 49.3 ± 13.6 50.5 ± 10.7 0.185
* Mean ± standard deviation.
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patibility differences. Grafting in the face of a minor
histocompatibility difference failed to generate second-set
skin-graft reactivity rejection, whereas grafting across a
major histocompatibility difference provided in vivo evi-
dence of accelerated skin-graft rejection and in vitro
evidence of cytolytic cells and antibodies. When grafting
of frozen bone with MHC mismatch was performed with-
out second-set skin grafting, antibodies were seen between
Days 30 and 50 with a peak at Day 40, but never achieved
high activity levels. There are some factors in experimental
design that can explain this difference to our observations.
First, Bos et al. performed iliac crest grafting with a high
bone marrow concentration [2]. It is well recognized that
bone marrow cells are strongly immunogenic. In our
experiments on intercalary bone, we removed bone marrow
content as much as possible in line with clinical practice.
Second, in the experiments of Bos et al. the grafts were
frozen to 208 for a minimum of 10 days, whereas our
grafts were deep frozen to 808 for a year. Third, Bos et al.
had an observation period of 50 days. At this time the
antibody response declined, and they stated that longer
followup studies would be highly desirable. We extended
the followup to 6 months.
Although Bos et al. found immune activity, histologic
evaluation at 50 days showed that frozen bone fared the
same regardless of the genetic relationship, and neither was
there any discernible difference in the scores of frozen
grafts that were mismatched or syngeneic [2]. Our histo-
logic results are in agreement with these observations, and
these results may explain clinical difﬁculties in correlating
HLA mismatches of frozen bone allografts with perfor-
mance and failures. It is assumed that T cells primed by the
indirect pathway may play the dominant role in the chronic
state of inﬂammation and rejection of allografts. Histologic
features of graft inﬂammation are well established as
inﬁltration with large numbers of lymphocytes and mac-
rophages, and a ﬁbroproliferative process [18]. In a study
of osteochondral allografts in dogs, the authors found that
the ingrowths of ﬁbrous connective tissue were directly
proportional to the immunogenicity of the bone grafts [28].
It also was reported that revascularization was slow in
mismatched grafts. In our study, the frozen allogeneic
grafts did as well as the syngeneic grafts by histologic
evaluations. The grafts consisted of a mixture of living and
dead bone tissue, but complete healing at the osteotomy
sites occurred in all cases. This reﬂects that the process of
creeping substitution of grafts by the ingrowths of vessels
is slow, and incorporation may be limited [5]. One rat in
each group showed localized inﬂammation and marrow
ﬁbrosis related to small dead bone fragments, most likely
emanating from the grafts. One may speculate that these
fragments represent a sign of early fatigue microdamage,
heralding a later graft fracture. But along with the antibody
tests, our histologic data indicate that there was no indirect
antigen presentation to the host T cells that might provoke
any inﬂammation or affect the healing of the graft.
Bone graft incorporation is a complicated process with
multiple variables inﬂuencing rate, pattern, and complete-
ness; one method of evaluation would not adequately show
the various aspects [27]. Our radiographic examinations
were in agreement with the histologic ﬁndings and showed
complete healing by complete bone bridging without gaps
in all grafts. However, successful incorporation of bone
grafts should result in a composite that can bear physio-
logic loads, and neither radiographic nor histologic
methods can measure the biomechanical competence of
grafted bones. Measurements of bone mineralization pro-
vide a valuable estimation of bone quantity and quality that
correlates to biomechanical properties, but the technique
cannot accurately predict biomechanical competence [16].
However, our data on bone mineralization and biome-
chanical testing showed that, at 6 months, the biomechan-
ical constructions were equivalent to intact bone; either
we used deep frozen grafts matched or mismatched for
MHC antigens. Few studies on bone grafting report
biomechanical data, but our ﬁndings agree with obser-
vations 11 months after fresh and frozen tissue antigen
matched and mismatched osteochondral allografts in
dogs [28].
Our observations suggest mismatches for MHC antigens
are not serious obstacles to transplantation of long-term
frozen-bone intercalary allografts. If these results can be
translated to the human setting, HLA matching of the bone
donor with the recipient does not, in itself, improve the
outcome of the transplantation.
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